aTyr Pharma provides plans regarding initiation of Phase 2 study of efzofitimod

aTyr Pharma provided additional details regarding its plans to initiate a Phase 2 study of its lead therapeutic candidate, efzofitimod, in patients with systemic sclerosis-associated interstitial lung disease following the clearance of an Investigational New Drug application by the U.S. Food and Drug Administration announced earlier this year. "We are thrilled to expand our efzofitimod clinical program to include a Phase 2 study in SSc-ILD with clearance of this IND, which is supported by preclinical data showing efzofitimod reduces lung and skin fibrosis in an animal model of SSc-ILD and clinical data demonstrating proof-of-concept for efzofitimod in patients with pulmonary sarcoidosis," said Sanjay Shukla, M.D., M.S., President and CEO of aTyr. "ILD is the leading cause of death in patients with scleroderma. Current treatment options may help to slow lung function decline but do not impact underlying disease or improve quality of life. There remains a medical need for more effective and safer therapies for patients with this debilitating disease."